https://www.selleckchem.com/products/bms-1166.html
At a median of 23 months (range 3-6 from diagnosis, 5/9 patients are in CCR or complete molecular remission (nilotinib, n=2; dasatinib, n=2; allo SCT, n=1) while 2/9 patients have died. We conclude that i) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and ii) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. This article is protected by copyright
Like
Comment
Share
